Bristol Myers Squibb Announces Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Biotech Investing
Merck's KEYTRUDA® Demonstrated Superior Disease-Free Survival Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma Following Surgery Pharmaceutical Investing
Aurinia Presents Data Demonstrating LUPKYNIS Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings Biotech Investing
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival Biotech Investing
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Contact the Firm Biotech Investing
AbbVie Submits Regulatory Applications for SKYRIZI® in Psoriatic Arthritis to FDA and EMA Biotech Investing
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology Annual Meeting Biotech Investing
FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device Medical Device Investing
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis Pharmaceutical Investing
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
